Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Beactica Therapeutics
Entity

Beactica Therapeutics

Tracked across 1 events · 7 articles · First seen Feb 17, 2026 · Last active Feb 17, 2026

Sentiment
80
Attention
4
Events
1
Relationships
3
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 80
Tech
Beactica, KU Leuven Secure EIC Grant for BEA-17
Beactica Therapeutics AB, a Swedish precision medicine company, has been awarded a EUR 2.5 million grant by the International===European Innovation Council to advance its precision immune therapy, BEA-17, for glioblastoma. This funding is non-dilutive and will enable the company to complete IND-enabling studies and move towards first-in-human clinical trials, significantly validating its immuno-epigenetic approach.
Feb 17, 2026 · 7 articles
Relationships (3)
KU Leuven collaborator ↔ Beactica Therapeutics Beactica Therapeutics AB and KU Leuven are collaborating on the GLIOBREAK projec
International===European Innovation Council ↔ Beactica Therapeutics Unknown
Per Källblad CEO ↔ Beactica Therapeutics Per Källblad is the CEO of Beactica Therapeutics AB.
NEWSDESK
Track Beactica Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.